ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

DateFriday, May 10, 2024
  
Time8:30 a.m. ET
  
Toll free (U.S.)800-274-8461
  
Conference ID4555224
  
Webcast (live and replay), under the “Investors” section
  

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-938-2239 and entering access code 4555224.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, leveraging its U.S. based manufacturing footprint, and delivering innovation in Established Brands. For more information, please visit our website .

Investor Relations Contact:

Lisa M. Wilson, In-Site Communications, Inc.

212-452-2793

SOURCE: ANI Pharmaceuticals, Inc.



EN
18/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferen...

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event  Date:Tuesday, May 14, 2024  Time:12:15pm ET  To schedule a 1x1 meeting with management, please contact   H.C. Wainwright 2nd Annual BioConnect Conference at N...

ANI Pharmaceuticals Inc: 1 director

A director at ANI Pharmaceuticals Inc sold 27,232 shares at 65.097USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

 PRESS RELEASE

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on...

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024  Time8:30 a...

 PRESS RELEASE

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®. "The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market. We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a tim...

 PRESS RELEASE

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patient...

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis --ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month. During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch